| Collaboration with Genentech on siRNA Therapeutics Development |
| |
| |
November 04 2008 |
| |
| |
RNA Interference Holds Potential for New Class of Drugs that Regulate Gene Function |
| |
WALTHAM, Mass. (November 4, 2008) – Thermo Fisher Scientific Inc., the world leader in serving science, has entered into a collaboration with Genentech, Inc.to develop novel small-interfering RNA (siRNA) therapeutic technologies for indications of interest to Genentech.
Under the collaboration agreement, Thermo Fisher Scientific will provide Genentech with siRNA design, stabilization, delivery and related RNA interference (RNAi) technologies from its RNAi Discovery and Therapeutic Services laboratory in Lafayette, Colorado. Genentech may use these technologies in the development of potential siRNA-based drugs. Such drugs would work by reducing, or silencing, the expression of specific genes implicated in disease. The research could extend drug discovery efforts to disease targets where traditional discovery technologies have not been successful.
“We believe the collaboration between Genentech and Thermo Fisher Scientific represents the joining of two leading-edge innovators aimed at advancing the development of siRNA-based drug technologies,” said Ian Jardine, vice president of global R&D for Thermo Fisher Scientific. “By combining Genentech’s expertise in the development of biological therapeutics with Thermo Fisher’s capabilities in RNAi and RNA chemistry, we hope to greatly advance this promising therapeutic class. Our work with Genentech will focus on developments that will enable in vivo target validation and potentially human therapeutic applications of RNAi technology.”
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit www.thermofisher.com.
The following constitutes a “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This press release contains forward-looking statements that involve a number of risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company’s Quarterly Report on Form 10-Q for the quarter ended September 27, 2008, under the caption “Risk Factors,” which is on file with the Securities and Exchange Commission (SEC) and available in the “Investors” section of our Website under the heading “SEC Filings.” Important factors that could cause actual results to differ materially from those indicated by forward-looking statements include risks and uncertainties relating to: competition and its effect on pricing, spending, third-party relationships and revenues; the need to develop new products and adapt to significant technological change; implementation of strategies for improving internal growth; general worldwide economic conditions and related uncertainties; use and protection of intellectual property; dependence on customers’ capital spending policies and government funding policies; realization of potential future savings from new productivity initiatives; the effect of changes in governmental regulations; the effect of exchange rate fluctuations on international operations; the effect of laws and regulations governing government contracts; the effect of competing with certain of our customers and suppliers; and the effect of rapid changes in the healthcare industry. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change and, therefore, you should not rely on these forward-looking statements as representing our views as of any date subsequent to today.
|
|
|
|
0 Items